211
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Current understanding of autoantibody against angiotensin II type 1 receptor in preeclampsia

, & ORCID Icon
Pages 4089-4094 | Received 07 Aug 2020, Accepted 02 Nov 2020, Published online: 29 Nov 2020
 

Abstract

Preeclampsia (PE) remains a leading cause of fetal and maternal mortality. Angiotensin II type 1 receptor autoantibody (AT1-AA) is implicated in the dysregulation of the renin-angiotensin-aldosterone system. A strong relationship between AT1-AA and the occurrence and severity of PE has been confirmed in previous literature. Recent evidences suggested that AT1-AA was responsible for blood pressure elevation, reactive oxygen species synthesis, and inflammatory factors release and engaged in multiple signaling cascades. The inhibition of AT1-AA might be a potential therapeutic target in future days. Here we reviewed the current understanding of AT1-AA, aiming to provide clarity surrounding the role of AT1-AA in PE.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by National Natural Science Foundation of China NO. 82071670 (Jinjun Liu), NO. 81972814 (Weiyi Feng), NO. 81771616 (Jinjun Liu), NO. 81471471 (Jinjun Liu) and NO. 81372379 (Weiyi Feng). Tkanks for Dr. Zhuo Zhao for his kind support and love during the whole writing.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.